UPB
NASDAQUpstream Bio Inc.
$9.32-0.29 (-3.02%)
News25/Ratings8
Price$9.32-0.04 (-0.43%)
01:30 PM07:45 PM
News · 26 weeks36-75%
2025-11-022026-04-26
Mix2190d
- SEC Filings9(43%)
- Other6(29%)
- Insider5(24%)
- Analyst1(5%)
Latest news
25 items- PRUpstream Bio to Present New Data from Phase 2 VIBRANT Trial of Verekitug at the ATS 2026 International ConferenceWALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced two upcoming poster presentations at the American Thoracic Society (ATS) 2026 International Conference in Orlando, FL, on Monday, May 18, 2026. The presentations feature new data from the Phase 2 VIBRANT trial evaluating verekitug, the only known antagonist to the thymic stromal lymphopoietin (TSLP) receptor currently in clinical development, in chronic rhinosinusitis with nasal polyps (CRSwNP). The data to be presented include the clinical effect of verekitug in
- SECSEC Form DEFA14A filed by Upstream Bio Inc.DEFA14A - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form DEF 14A filed by Upstream Bio Inc.DEF 14A - Upstream Bio, Inc. (0002022626) (Filer)
- ANALYSTUpstream Bio downgraded by Evercore ISI with a new price targetEvercore ISI downgraded Upstream Bio from Outperform to In-line and set a new price target of $15.00
- SECSEC Form 8-K filed by Upstream Bio Inc.8-K - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form 424B5 filed by Upstream Bio Inc.424B5 - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form S-8 filed by Upstream Bio Inc.S-8 - Upstream Bio, Inc. (0002022626) (Filer)
- SECSEC Form 10-K filed by Upstream Bio Inc.10-K - Upstream Bio, Inc. (0002022626) (Filer)
- SECUpstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Upstream Bio, Inc. (0002022626) (Filer)
- PRUpstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results– Company to pursue Phase 3 development strategy designed to deliver best-in-class efficacy with a high-dose quarterly regimen in broad patient populations in both severe asthma and CRSwNP – – Company plans to initiate dosing in Phase 3 trials in both severe asthma and CRSwNP in Q1 2027 – – Reported positive top-line results from Phase 2 VALIANT trial of verekitug in patients with severe asthma in February 2026, demonstrating significant improvements in asthma exacerbations and lung function – – Presented additional analyses from Phase 2 VIBRANT trial at AAAAI, reinforcing verekitug's therapeutic potential in CRSwNP – – Strong cash position of $341.5 million expected to fund planned oper
- INSIDERCFO and COO Gray Michael sold $7,915 worth of shares (852 units at $9.29), decreasing direct ownership by 3% to 29,648 units (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Medical Officer Deykin Aaron sold $8,305 worth of shares (894 units at $9.29), decreasing direct ownership by 3% to 32,687 units (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Executive Officer Sutherland Everett Rand sold $19,444 worth of shares (2,093 units at $9.29), decreasing direct ownership by 3% to 72,907 units (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERGeneral Counsel Ambrose Allison sold $4,413 worth of shares (475 units at $9.29), decreasing direct ownership by 3% to 16,525 units (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Business Officer Houghton Adam sold $6,494 worth of shares (699 units at $9.29), decreasing direct ownership by 3% to 24,301 units (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- PRUpstream Bio Presents Additional Analyses from the Phase 2 VIBRANT Trial of Verekitug in Chronic Rhinosinusitis with Nasal Polyps at 2026 AAAAI Annual Meeting– Primary endpoint of endoscopic nasal polyp score (NPS) showed reduction of -1.95 (p < 0.0001) in new analysis with adjustment for concomitant rescue therapy use – – Secondary endpoints also provided strong efficacy data in new analyses, including reduction in nasal congestion score (NCS) by -0.96 (p < 0.0001) – WALTHAM, Mass., March 01, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today presented additional data from the Phase 2 VIBRANT clinical trial evaluating verekitug in participants with chronic rhinosinusitis with nasal polyps (CRSwNP). The
- PRUpstream Bio to Participate in Upcoming March Investor ConferencesWALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care Conference, Boston, MAWednesday, March 4, 2026, Fireside Chat - 9:50 a.m. ET2026 Leerink Partners Global Healthcare Conference, Miami, FLMonday, March 9, 2026, Fireside Chat - 1:40 p.m. ET Live webcasts of the presentations will be available under the Events tab on the Investors section o
- SECUpstream Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure8-K - Upstream Bio, Inc. (0002022626) (Filer)
- SECUpstream Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Upstream Bio, Inc. (0002022626) (Filer)
- PRUpstream Bio Reports Positive Top-line Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma– Verekitug provided statistically significant and clinically meaningful reductions in annualized asthma exacerbation rate (AAER) with 100 mg q12 and 400 mg q24 week dosing – – Verekitug also delivered clinically meaningful improvements in lung function (FEV1) and exhaled nitric oxide (FeNO) with both dose regimens – – Verekitug was generally well tolerated, with a safety profile consistent with prior studies – – Over 90% of eligible patients have rolled over to the Phase 2 VALOUR long-term extension study – – Upstream Bio to advance verekitug into Phase 3 trials in severe asthma and CRSwNP following planned regulatory interactions – – Management will host a live webcast today at 8:00
- PRUpstream Bio to Host Webcast to Report Top-Line Results from the Phase 2 VALIANT Trial of Verekitug in Patients with Severe AsthmaWALTHAM, Mass., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced it will report top-line results from the Phase 2 VALIANT trial of verekitug, the only known antagonist currently in clinical development that targets and inhibits the thymic stromal lymphopoietin (TSLP) receptor, on Wednesday, February 11, 2026 at 8:00 a.m. ET. The VALIANT trial (NCT06196879) is a Phase 2 global, randomized, double-blind, placebo-controlled, dose-ranging, parallel group clinical trial that evaluated the safety and efficacy of verekitug for up to 60
- INSIDERChief Business Officer Houghton Adam was granted 25,000 shares (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERChief Medical Officer Deykin Aaron was granted 32,000 shares, increasing direct ownership by 2,024% to 33,581 units (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERGeneral Counsel Ambrose Allison was granted 17,000 shares (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)
- INSIDERCFO and COO Gray Michael was granted 30,500 shares (SEC Form 4)4 - Upstream Bio, Inc. (0002022626) (Issuer)